Histochem Cytochem 63 (8), 575591
Invited to give a presentation on GLUT2, he quickly gained the attention of people from Novo Nordisk when he briefly mentioned his work on the GLP-1 receptor at the end of his talk which he had not yet published
[11] [12] These cardiovascular benefits have influenced treatment algorithms, with guidelines recommending GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and atherosclerotic cardiovascular disease
Extended data figures and tables Extended Data Figure 1 GLP-1R crystallization and structure determination
Key Takeaways Retatrutide is a once-weekly injectable triple agonist targeting GLP-1, GIP, and glucagon receptors Starting dose is typically 1 mg weekly, titrating up gradually to minimize side effects Maintenance doses range from 8 mg to 12 mg weekly based on individual response Titration is critical for balancing weight loss efficacy with tolerability Clinical trials show significant weight reduction compared to placebo Always work with a healthcare provider to determine your optimal dosing schedule Overview of Retatrutide What is Retatrutide
The half-life of oral semaglutide is approximately 1 week, aligning with subcutaneously administered form (102)
